Patents by Inventor Shuh Narumiya
Shuh Narumiya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230111840Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.Type: ApplicationFiled: December 7, 2022Publication date: April 13, 2023Applicants: Kyoto University, Astellas Pharma Inc.Inventors: Shimon SAKAGUCHI, Naganari OHKURA, Norihisa MIKAMI, Shuh NARUMIYA, Masahiko AKAMATSU, Guliang XIA, Hironori HARADA, Naoto NAKAMURA, Satoru UJIHARA, Hisao HAMAGUCHI
-
Patent number: 11578067Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.Type: GrantFiled: January 30, 2018Date of Patent: February 14, 2023Assignees: KYOTO UNIVERSITY, ASTELLAS PHARMA INC.Inventors: Shimon Sakaguchi, Naganari Ohkura, Norihisa Mikami, Shuh Narumiya, Masahiko Akamatsu, Guliang Xia, Hironori Harada, Naoto Nakamura, Satoru Ujihara, Hisao Hamaguchi
-
Publication number: 20210113529Abstract: Provided is a pharmaceutical for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability. The inventors of the present invention have made investigations on a pharmaceutical for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability, and have confirmed that a selective S1P receptor agonist having agonist activity at an S1P1 receptor has an intraocular neovascularization-reducing action and an intraocular vascular permeability-reducing action, thus completing the present invention.Type: ApplicationFiled: February 1, 2019Publication date: April 22, 2021Applicants: KYOTO UNIVERSITY, Astellas Pharma Inc.Inventors: Hideaki HARA, Shuh NARUMIYA, Tomohiro AOKI, Ichiro ARAMORI, Rie YAMAMOTO
-
Publication number: 20190382403Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.Type: ApplicationFiled: January 30, 2018Publication date: December 19, 2019Applicants: Kyoto University, Astellas Pharma Inc.Inventors: Shimon SAKAGUCHI, Naganari OHKURA, Norihisa MIKAMI, Shuh NARUMIYA, Masahiko AKAMATSU, Guliang XIA, Hironori HARADA, Naoto NAKAMURA, Satoru UJIHARA, Hisao HAMAGUCHI
-
Publication number: 20150190416Abstract: The present invention provides a highly effective substance having a filaggrin production-promoting action. The present invention also provides a therapeutic agent useful for treating a skin disease, in particular, atopic dermatitis associated with reduced filaggrin production. As a result of intensive studies on a filaggrin production promoter, it has been found that A) an N-quinolylbenzamide derivative (Compound 1), B) ivermectin (Compound 2), or C) a phenylalaninamide derivative (Compound 3) promotes production of filaggrin in skin and satisfactorily improves a water retention ability and barrier function of the stratum corneum. The present invention relates to a filaggrin production promoter containing a certain N-quinolylbenzamide derivative or a pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: July 12, 2013Publication date: July 9, 2015Inventors: Kenji Kabashima, Atsushi Otsuka, Gyohei Egawa, Hiromi Doi, Akiko Maekawa, Shuh Narumiya
-
Publication number: 20060128810Abstract: The present invention relates to a prophylactic and/or therapeutic agent for an allergic disease which contains a compound having an agonistic activity to EP3 receptor that is one of the prostaglandin E2 receptor subtypes. More specifically, a compound having an agonistic activity to EP3 receptor is effective in therapy of an allergic respiratory disease such as bronchial asthma, pediatric asthma, allergic asthma, or atopic asthma, and a selective agonistic compound can be expected to induce a more remarkable therapeutic effect.Type: ApplicationFiled: October 9, 2003Publication date: June 15, 2006Applicant: Kyoto UniversityInventor: Shuh Narumiya
-
Publication number: 20060058394Abstract: The treatment and/or prophylactic drugs of post-traumatic stress disorder (PTSD) containing compounds (EP1 agonists), which activate EP1 receptor that is subtype of prostaglandin E2 receptor, as an active ingredient. EP1 agonists such as (13E)-(11?,15S,17S)-2,5-ethano-6,9-dioxo-11,15-dihydro-17,20-dimethylprosta-13-enoic acid, PGE1, or PGE2, etc. are useful for the treatment of post-traumatic stress disorder (PTSD).Type: ApplicationFiled: October 14, 2005Publication date: March 16, 2006Inventors: Shuh Narumiya, Takayuki Maruyama
-
Publication number: 20040122100Abstract: The treatment and/or prophylactic drugs of post-traumatic stress disorder (PTSD) containing compounds(EP1 agonists), which activate EP1 receptor that is subtype of prostaglandin E2 receptor, as an active ingredient. EP1 agonists such as (13E)-(11&agr;, 15S, 17S)-2, 5-ethano-6, 9-dioxo-11, 15-dihydro-17, 20-dimethylprosta-13-enoic acid, PGE1, or PGE2, etc. are useful for the treatment of post-traumatic stress disorder (PTSD).Type: ApplicationFiled: September 16, 2003Publication date: June 24, 2004Inventors: Shuh Narumiya, Takayuki Maruyama
-
Patent number: 6111072Abstract: An objective of the present invention is to provide an activated Rho protein target protein derived from a human and a gene coding for the same. The present invention provides a protein derived from a human and a derivative thereof which has the following characteristics: (1) having activated Rho protein binding activity, (2) having profilin binding activity, (3) the gene coding for the protein being located at q31.2 of chromosome 5, and (4) having a molecular weight of about 150 kDa as measured by SDS-PAGE. Respiratory tract hypersensitivity, bronchial asthma, acute myelocytic leukemia (AML) and myelodysplasia syndrome (MDS) can be diagnosed using the nucleotide sequence coding for this protein.Type: GrantFiled: July 24, 1997Date of Patent: August 29, 2000Assignee: Kirin Beer Kabushiki KaishaInventors: Shuh Narumiya, Nobuaki Takahashi
-
Patent number: 6013499Abstract: The object of the present invention is to provide a target protein for the activated Rho protein. The present invention is a protein having the activated Rho protein binding activity and protein kinase activity, or derivatives thereof. The molecular weight of the protein is about 160 kDa as measured by SDS-PAGE. The protein kinase activity of the protein is enhanced when it binds to the activated Rho protein.Type: GrantFiled: July 24, 1996Date of Patent: January 11, 2000Assignee: Kirin Beer Kabushiki KaishaInventors: Shuh Narumiya, Akihiro Iwamatsu
-
Patent number: 5804415Abstract: Disclosed are (1) a protein capable of receiving PGE, (2) a recombinant DNA coding for said protein, (3) a vector having said DNA, (4) a transformant carrying said vector, and (5) a method for producing said protein wherein said transformant is cultured in a culture medium, the protein being useful not only in cloning other PGE receptor genes, clarifying the structure of PGE receptors and elucidating the function of PGE, but also in searching for PGE antagonists and agonists and so on.Type: GrantFiled: July 22, 1996Date of Patent: September 8, 1998Assignee: Takeda Chemical Industries, Ltd.Inventors: Atsushi Ichikawa, Shuh Narumiya
-
Patent number: 5576192Abstract: Disclosed are (1) a protein capable of receiving PGE, (2) a recombinant DNA coding for said protein, (3) a vector having said DNA, (4) a transformant carrying said vector, and (5) a method for producing said protein wherein said transformant is cultured in a culture medium, the protein being useful not only in cloning other PGE receptor genes, clarifying the structure of PGE receptors and elucidating the function of PGE, but also in searching for PGE antagonists and agonists and so on.Type: GrantFiled: February 17, 1995Date of Patent: November 19, 1996Assignee: Takeda Chemical Industries, Ltd.Inventors: Atsushi Ichikawa, Shuh Narumiya
-
Patent number: 5084214Abstract: Phenolic thioethers of the formula: ##STR1## wherein R is a hydrogen atom or a protective group for carboxyl, X is a straight or branched C.sub.4 -C.sub.15 alkylene group, a straight or branched C.sub.1 -C.sub.15 alkylene group having a phenylene group or a straight or branched C.sub.2 -C.sub.15 alkenylene group, and their salts, which inhibit the denaturation of low density lipoproteins (LDL) and the incorporation of LDL by macrophages and are useful as anti-arteriosclerosis agents.Type: GrantFiled: May 31, 1989Date of Patent: January 28, 1992Assignee: Shionogi & Co., Ltd.Inventors: Toru Kita, Shuh Narumiya, Masayuki Narisada, Fumihiko Watanabe, Saichi Matsumoto, Masami Doteuchi
-
Patent number: 4954514Abstract: (Di-tert-butylhydroxyphenyl)thio derivatives of the formula: ##STR1## wherein R is cyano, carbamoyl, or 5-tetrazolyl; n is an integer of 2 to 6; provided that when R is cyano, n is not 2; or a pharmaceutically acceptable salt thereof; useful in treating arterioschlerosis, ulcer, inflammation, allergy, or the like.Type: GrantFiled: December 18, 1989Date of Patent: September 4, 1990Assignee: Shionogi & Co, LtdInventors: Toru Kita, Shuh Narumiya, Masayuki Narisada, Fumrhio Watanabe, Masami Doteuchi, Takuji Mizui
-
Patent number: 4812457Abstract: Permeability characterized in that the carboxy group at 1-position of the prostaglandin is combined with a cell membrane permeable substance having hydroxy group or amino group through the intermediation of an ester bond to the hydroxy group or an amide bond to the amino group are novel and have improved cell membrane permeability.Type: GrantFiled: January 29, 1988Date of Patent: March 14, 1989Assignees: Research Development Corporation, Masami TsuboshimaInventors: Shuh Narumiya, Osamu Hayaishi, Yoshiharu Kimura, Masami Tsuboshima